175 related articles for article (PubMed ID: 27553066)
1. Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.
Evans M; Gundgaard J; Hansen BB
Diabetes Ther; 2016 Dec; 7(4):809-823. PubMed ID: 27553066
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.
Luo Q; Zhou L; Zhou N; Hu M
Front Public Health; 2022; 10():1016937. PubMed ID: 36330105
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials.
Fulcher G; Mehta R; Fita EG; Ekelund M; Bain SC
Diabetes Ther; 2019 Feb; 10(1):107-118. PubMed ID: 30474818
[TBL] [Abstract][Full Text] [Related]
4. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
6. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
8. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Niu YL; Zhang Y; Song ZY; Zhao CZ; Luo Y; Wang Y; Yuan J
Iran J Public Health; 2024 Feb; 53(2):313-322. PubMed ID: 38894842
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
Valentine WJ; Pollock RF; Plun-Favreau J; White J
Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
[TBL] [Abstract][Full Text] [Related]
12. Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.
Pedersen-Bjergaard U; Kristensen PL; Nørgaard K; Perrild H; Jensen T; Thorsteinsson B; Nikolajsen A; Tarnow L
Curr Med Res Opin; 2016 Oct; 32(10):1719-1725. PubMed ID: 27326862
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Shao H; Alsaleh AJO; Dex T; Lew E; Fonseca V
Diabetes Ther; 2022 Sep; 13(9):1659-1670. PubMed ID: 35930188
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.
Lalić N; Russel-Szymczyk M; Culic M; Tikkanen CK; Chubb B
Diabetes Ther; 2018 Jun; 9(3):1201-1216. PubMed ID: 29700772
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
McCrimmon RJ; Palmer K; Alsaleh AJO; Lew E; Puttanna A
Diabetes Ther; 2022 Jun; 13(6):1203-1214. PubMed ID: 35543869
[TBL] [Abstract][Full Text] [Related]
16. A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.
Jiang Y; Liu R; Xuan J; Lin S; Zheng Q; Pang J
Clin Drug Investig; 2023 Apr; 43(4):251-263. PubMed ID: 36943659
[TBL] [Abstract][Full Text] [Related]
17. Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.
Langer J; Wolden ML; Shimoda S; Sato M; Araki E
Diabetes Ther; 2019 Aug; 10(4):1347-1356. PubMed ID: 31168694
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.
Evans M; Mehta R; Gundgaard J; Chubb B
Diabetes Ther; 2018 Oct; 9(5):1919-1930. PubMed ID: 30097995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
